How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?

It was very exciting to see PARADIGM presented as a plenary at ASH, and I look forward to the manuscript! Interpreting the findings in the context of the enrolled patients is very important. The median age of enrolled patients was approximately 65 years in both arms, and ~75% of enrolled patients had adverse-risk disease by ELN22. There were very few enrolled patients with ELN22 favorable-risk and intermediate-risk disease, so it's difficult to have meaningful takeaways from those populations. With this in mind, for fit patients (particularly over the age of 60) with ELN22 adverse-risk disease who are allogeneic transplant candidates, I feel that PARADIGM supports the use of HMA + venetoclax over standard intensive chemotherapy, given the i...